 Blueprint unveiled the long-awaited results of its study in indolent systemic mastocytosis on Wednesday, and the biotech stock crashed. The post Blueprint Medicines Stock Hammered As Long-Awaited Test Results Disappoint appeared first on Investors Business Daily. 